Creative Medical Technology CELZ

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.04 (-1.83%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Creative Medical Technology (CELZ) Business Model and Operations Summary
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Key Insights

Creative Medical Technology (CELZ) Core Market Data and Business Metrics
  • Latest Closing Price

    $2.18
  • Market Cap

    $5.29 Million
  • Average Trade Volume

    129,478 Shares
  • Total Outstanding Shares

    2.59 Million Shares
  • CEO

    Mr. Timothy Warbington
  • Total Employees

    4
  • IPO Date

    April 30, 2009
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Primary Exchange

    NASDAQ
  • Headquarters

    211 E. Osborn Rd., Phoenix, AZ, 85012

Earnings Reports

Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

Short Volume

Daily short volume activity identifies short-term trading pressure and potential price volatility

Revenue Breakdown

Distribution of revenue across unique business segments & geographies

Historical Stock Splits

Execution DateSplit Amount

Historical Dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about CELZ from trusted financial sources